These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 32722100)

  • 1. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.
    Nishikawa H; Enomoto H; Nishiguchi S; Iijima H
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.
    Maslennikov R; Alieva A; Poluektova E; Zharikov Y; Suslov A; Letyagina Y; Vasileva E; Levshina A; Kozlov E; Ivashkin V
    World J Gastroenterol; 2023 Jul; 29(27):4236-4251. PubMed ID: 37545638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory Bowel Diseases and Sarcopenia: The Role of Inflammation and Gut Microbiota in the Development of Muscle Failure.
    Nardone OM; de Sire R; Petito V; Testa A; Villani G; Scaldaferri F; Castiglione F
    Front Immunol; 2021; 12():694217. PubMed ID: 34326845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between intestinal microbial dysbiosis and primary liver cancer.
    Zhang L; Wu YN; Chen T; Ren CH; Li X; Liu GX
    Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):149-157. PubMed ID: 30661942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
    Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
    Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
    Giannelli V; Di Gregorio V; Iebba V; Giusto M; Schippa S; Merli M; Thalheimer U
    World J Gastroenterol; 2014 Dec; 20(45):16795-810. PubMed ID: 25492994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of mucosa-associated microbiota dysbiosis in the ascending colon in hepatitis C virus post-sustained virologic response cirrhotic patients.
    Midori Y; Nosaka T; Hiramatsu K; Akazawa Y; Tanaka T; Takahashi K; Naito T; Matsuda H; Ohtani M; Nakamoto Y
    Front Cell Infect Microbiol; 2024; 14():1371429. PubMed ID: 38650735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The critical role of gut microbiota dysbiosis in skeletal muscle wasting: a systematic review.
    Nikkhah A; Ejtahed HS; Ettehad Marvasti F; Taghavi M; Pakmehr A; Hajipour F; Larijani B
    J Appl Microbiol; 2023 Jan; 134(1):. PubMed ID: 36626794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiota, cirrhosis, and the emerging oral-gut-liver axis.
    Acharya C; Sahingur SE; Bajaj JS
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbial dysbiosis as a limiting factor in the management of primary and secondary sarcopenia: an Asian Indian perspective.
    Bhattacharya S; Bhadra R; Schols AMWJ; Sambashivaiah S
    Curr Opin Clin Nutr Metab Care; 2020 Nov; 23(6):404-410. PubMed ID: 32868683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact.
    Nishikawa H; Enomoto H; Nishiguchi S; Iijima H
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.
    Muñoz L; Borrero MJ; Úbeda M; Conde E; Del Campo R; Rodríguez-Serrano M; Lario M; Sánchez-Díaz AM; Pastor O; Díaz D; García-Bermejo L; Monserrat J; Álvarez-Mon M; Albillos A
    Hepatology; 2019 Sep; 70(3):925-938. PubMed ID: 30414342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis.
    Macnaughtan J; Jalan R
    Am J Gastroenterol; 2015 Oct; 110(10):1399-410; quiz 1411. PubMed ID: 26416191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of uremic dysbiosis to insulin resistance and sarcopenia.
    Uchiyama K; Wakino S; Irie J; Miyamoto J; Matsui A; Tajima T; Itoh T; Oshima Y; Yoshifuji A; Kimura I; Itoh H
    Nephrol Dial Transplant; 2020 Sep; 35(9):1501-1517. PubMed ID: 32535631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections.
    Ancona G; Alagna L; Lombardi A; Palomba E; Castelli V; Renisi G; Dondossola D; Iavarone M; Muscatello A; Gori A; Bandera A
    Infect Immun; 2021 Oct; 89(11):e0037621. PubMed ID: 34460287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.